Slides
Page 1
23 September 2026 ASX SMID Caps Conference Developing new therapies to treat kidney diseases with unmet clinical needsAuthorised for lodgement by the Board of the Company
Page 2
2 Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, including but not limited to those factors outlined in the most recent Dimerix Limited Annual Report.
Page 3
3 ~$1.9 billion* 5 commercial licensing partners *total upfront and potential milestone payments + royalties on net sales DMX-200: Phase 3 Global Opportunity 1. Based on ASX releases 05 October 2023, 27 May 2024, 07 January 2025, 01 May 2025 and 16 June 2026; SEA = Southeast Asia, G CC = Gulf Cooperation Council; 2. AS release 10 March 2026; 3. ASX release 28 April 2026; 3. Guruswamy Sangameswaran KD, Baradhi KM. Focal Segmental Glomerulosclerosis (July 2021), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/; 4. ASX release 11 March 2024 and 28 April 2026; 5. ASX releases: 14 December 2015, 21 November 2018, 07 June 2021 and 30 September 2025 FSGS indication is a rare disease that causes scarring of the kidney, leading to irreversible damage3 Orphan drug designations regulatory, marketing exclusivity and pricing benefits in key territories5 5 commercial partners DMX-200 licensed USA, EU, Canada, Australia, NZ, Japan, China, S.Korea, SEA and GCC1 up to $1.9 billion in total development and sales milestone payments plus royalties on net sales1 Phase 3 trial recruitment complete in trial of DMX-200 in focal segmental glomerulosclerosis (FSGS)2 Reduced risk Proteinuria endpoint passed blinded interim (futility) assessment1 Blinded review confirmed ACTION3 statistically powered (>90%) to demonstrate statistical significance of predicted proteinuria treatment effect of DMX-2004
Page 4
4 Cycle of damage in glomerular diseases What is FSGS? Focal = some Segmental = sections Glomerulo = of the kidney filtering units Sclerosis = are scarred 3 Pro-inflammatory environment drives sclerosis and fibrosis that is permanent and non-reversable 2 Constant pressure causes inflammation of glomerulus and influx of inflammatory immune cells 1 High blood pressure causes hyperfiltration within filter units (glomeruli) of the kidney1 Fewer kidney cells drive higher blood pressure and further hyperfiltration and inflammation As cells die, glomerular become scarred and protein leaks into the urine (proteinuria) Glomeruli exposed to stress from high blood pressure 1. Lewis, E. J. et al. (2001), New Engl J Medicine 345, 851 –860 DMX-200 Existing blood pressure medication
Page 5
5 phase 3 clinical trial 1. ASX release 11 March 2024, Predictive Power statistical model using industry standard as set by the independent renal biostat istician consultant for Dimerix, b linded interim Phase 3 analysis data does not guarantee a statistically significant outcome at the end of the trial; 2. ASX release 28 April 2026; 3. number and % of eligible patients who have completed 2 years treatment and elected to enter the OLE as at 15 September 2026; ARB = angiotensin receptor blocker; uPCR = urinary proteinuria; eGFR = estimated glomerular filtration rate (kidney function); A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB (n=≥286) ARB + DMX-200 ARB + placebo Planned blinded statistical powering review2 Phase 3 Trial Timeline Final analysis: Primary = uPCR Secondary = eGFR2 @104 weeks Background • Patients recruited, then screened and stabilised on background medications • Patients randomised to receive drug or placebo • DXB remains blinded at all times during study Open Label Extension DMX-200 87/95 (92%)3 patients enrolled in open label extension study to date ACTION3 Study End European Renal Association Posters 2025 Successful interim analysis1 (using statistical measure) 72 patients @ 35 weeks (% change in uPCR) demonstrated DMX-200 was performing better than placebo at that point in time1 ACTION3 remains appropriately statistically powered (>90%) to demonstrate a treatment effect for proteinuria primary endpoint2
Page 6
6 U P T O A$1.9bn in upfront and potential milestone payments + royalties P O T ENT IA L V A L U E B Y T IM ING RECEIVED / CONTRACTED A$81m Upfront fees On signing NEARER-TERM POTENTIAL A$237m Pre-launch milestones Before commercial launch LONGER-TERM POTENTIAL A$1.56bn Post-launch milestones Following commercial launch + +A$318m upfront + potential pre-launch value FIVE PARTNERS | DIVERSIFIED GEOGRAPHIC EXPOSURE United States1 A$48m upfront Up to $A892m milestones Low-teen – low twenties % royalties China, S.Korea, SEA2 A$14.1m upfront Up to $A467m milestones 10 – 15% royalties EU, AU, NZ, CA3 A$10.8m upfront Up to $A219m milestones Mid-teen – 20% royalties Japan4 A$7.2m upfront Up to $100m milestones 15 – 20% royalties Middle East5 A$0.5m upfront Up to $120m milestones Starting at 30% royalties INVESTOR TAKEAWAY: Multiple potential revenue streams, with development and commercialisation risk shared across regional partners DMX-200: partnerships creating diversified revenue potential 1. Based on US conversions & further terms outlined in ASX Announcement on 01 May 2025; 2. Based on US conversions & further terms outlined in ASX Announcement on 16 June 2026; SEA = South East Asia; 3. Based on Euro conversions & further terms outlined in ASX Announcement on 5 October 2023, EU = Europe, AU = Australia, NZ = New Zleand, CA = Canada; 4. Based on Japanese ¥ Yen conversions & further terms outlined in ASX Announcement on 7 January 2025 ; 5. Based on US dollar conversions & further terms outlined in ASX Anno uncement on 27 May 2024, Middle East includes GCC countries + Iraq
Page 7
7 DMX-652: Phase 2 in acute kidney injury A complementary, clinical-stage pipeline addition 1. Dimerix internal analysis; Mission Therapeutics MTX -652 development file; 2. Zarbock et al, Intensive Care Med 2023; Vervoort et al, Ann Thorac Surg 2023; 3. Dimerix internal market analysis consensus figure based on meta-analysis of 21 market reports (2026) ; Includes China and Japan markets, label expansion into sep sis-associated AKI (SA-AKI) and contrast-associated AKI Large value potential • Secured a Phase 2 ready asset, which is already FDA cleared & manufactured • Substantial work to date undertaken by originator means significant early risk already removed1 First and best in class • First-in-class USP30 target that promotes renewal of mitochondria • DMX-652 targets one of the emerging key drivers of kidney injury and reduces both cellular energy failure and inflammation Leverages existing expertise • Dimerix team are experts in kidney disease; capable of identifying high value assets • Experienced in-house team with proven track record of advancing high value assets through clinical development and into commercialisation Large and growing market • No approved therapy for high-risk acute kidney injury patients and growing demand for new therapies2 • US$3.5 Billion in 2026 • est. US$7.5 Billion by 2036 Strategic value • Dimerix has significant optionality over the development and commercialisation direction of DMX-652, as the outright asset owner • DMX-652 has the potential to be used for a variety of other indications, many of which may also have large markets and unmet medical needs
Page 8
8 What is AKI associated with cardiac surgery ~26% of patients undergoing cardiac surgery suffer kidney injury Mitochondria = “batteries” for the kidney cell The kidney has the second-highest mitochondrial content and oxygen consumption in the body to fuel intense energy demands Cardiac Surgery1 Cardiopulmonary bypass starves the kidney of oxygen (ischaemia) and causes oxidative stress in kidney cells Kidney starved of oxygen Ischaemia2 Healthy mitochondria Currently no approved disease-modifying therapies Reperfusion: restores blood flow to kidney3 kidney damage caused by a massive influx of reactive oxygen species (ROS) that leads to cell death Mitochondria rupture Sudden decline in kidney function (hours) AKI Drives ICU stays, dialysis, mortality and/or progression to Chronic Kidney Disease Damaged mitochondria causes rupture of the mitochondrial membrane Source: Scurt FG et al, Kidney360 2024; Zarbock A et al, Intensive Care Med 2023; KDIGO clinical practice guidelines for AKI increases to 30-50% in high-risk patients
Page 9
9 A multicentre, double-blind, randomised, placebo-controlled study evaluating the safety and efficacy of DMX-652 in patients at high risk of AKI following cardiac surgery (n=160) Source: Mission Therapeutics MTX -652 Phase 2 protocol (FDA Study-May-Proceed, 2023); Dimerix MTX-652 development plan (2026); MAKE 30 & MAKE 90 = Major Adverse Kidney Events occurring at 30 or 90 days Proposed phase 2 clinical trial design 160 patients · 28 days on drug · 90-day follow-up · ~25 sites in US / EU / Australia Primary endpoint Secondary endpoints AKI incidence by 7 days post-surgery Screening/randomisation • Patients identified as high-risk for AKI • Stabilised on background medication pre-surgery • Standard peri-operative and post- operative care continues throughout Treatment phase Placebo N=~80 DMX-652 N=~80 Follow up Day 0 Day of surgery Day 7 Day 28 Day 90 Safety and tolerability PK MAKE30 MAKE90
Page 10
10 Strategic fit: shared renal capabilities, shared regulatory/clinical infrastructure, shared small-molecule know-how DMX-200 and DMX-652: complementary growth pillars 1. ASX release 10 March 2026; 2. ASX releases March 2024 and April 2026; 3. ASX releases 05 October 2023, 27 May 2024, 07 January 2025; 01 May 2025 and 16 June 2026; 4. ASX release 17 July 2026 1Focal Segmental Glomerulosclerosis (FSGS) rare kidney disease 1 Acute kidney injury associated with cardiac surgery 2CCR2 inhibitor that modulates inflammatory pathways involved in kidney damage 2 USP30 inhibitor designed to enhance mitophagy and mitochondrial quality control in damaged cells 3existing in-house infrastructure and global network 3 Can leverage existing expertise in clinical, regulatory, manufacturing, nephrology networks, know-how, and commercial relationships 4 4 provides a new growth engine, with an open IND, FDA clearance to proceed to Phase 2, and completed Phase 1 safety studies more advanced, near-commercialisation asset with Phase 3 fully recruited and commercial partnering activity Shared kidney disease focus Different Mechanisms of Action Shared Development Infrastructure Balanced Risk and Timing DMX-200 DMX-652
Page 11
11 Disciplined, stage-gated capital deployment focused on the clinical value inflection1 Key potential value inflection points Asset acquisition Patents assigned; Phase 2 ethics submission; Clinical site initiation First patient dosed in Phase 2 50% recruitment; Phase 2 interim / futility Phase 2 readout Preparation for Phase 3 DMX-652 H2 2026 H1 2027 H2 2027 H1 2028 H2 2028 Paediatric recruitment completion; first patient completes open label extension study ACTION3 Phase 3 FSGS readout NDA dossier submission DMX-200 Two clinically differentiated assets in renal disease, addressing two separate high unmet need indications with independent timelines; building a steady cadence of value-creating milestones Potential for additional licensing partners in available territories 1. Based on current anticipated activities timeline Phase 3 IDMC safety review
Page 12
12 Corporate overview 1. As at 15 September 2026; 2. Past 90 trading days liquidity as at 15 September 2026; 3. Shareholder register as at 15 September 2026; 3. ASX release 28 August 2026; 4. ASX release 3 September 2026 Ticker Symbol ASX: DXB Cash Balance (Jun26)* $16.2 million Market Capitalisation1 $150 million Share price1 $0.25 Total ordinary shares on issue1 600,396,776 Average Daily Liquidity by value for past 90 trading days2 $0.55 million S H A R E P R I C E S U B S T A N T I A L S H A R E H O L D E R S 3 Position Holder Name Holding % IC 1 Mr P Meurs 92,040,374 15.3% TOTAL (TOP 5) Shareholders 153,680,631 25.6% *excluding ~$48.1million: • AU$14.1 million Everest upfront payment received; 3 and • $34 million available facility 4
Page 13
W E L L P O S I T I O N E D TO D E L I V E R AGA I N ST ST R AT E G I C P L A N Dimerix HQ 425 Smith St, Fitzroy 3065 Victoria, Australia T. +61 1300 813 321 E. investor@dimerix.com (ASX:DXB) A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on kidney diseases. ESG Statement Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve its ESG performance demonstrate a strong, well-informed management attitude and a values led culture that is both alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.